Health Trials

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

ConditionsB Lymphocytic LeukemiaB Lymphoblastic Lymphoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-18
SponsorZhu Xiaofan

About this trial

To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children

Eligibility criteria

Qualifiers

Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥

Recurrence after bone marrow transplantation;

Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined

Creatinine ≤1.5×ULN;

Disqualifiers

1, severe cardiac insufficiency, left ventricular ejection fraction <50%;

Trial design

Treatments tested in this trial

  • CAR T cell injection

Treatment groups

60 Participants
are divided into 1 treatment group

Locations

2
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences300020, TianjinTianjin Municipality, China
InstituteHBDH300020, TianjinTianjin Municipality, China

Sponsors and collaborators

Zhu Xiaofan

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China

Sponsor institution

Source ClinicalTrials.gov